Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 1, 2025
Daily News
July 1, 2025
- Japan’s Contract Rep Ratio Hits Record as Biotechs, Foreign Firms Drive Demand
July 1, 2025
- Ono Targets over 800 Billion Yen in FY2035 Sales under Growth Scenario: CEO
July 1, 2025
- Japan Publishes 2025 Strategy Report on Clinical Trials, Backs Single IRB as General Rule
July 1, 2025
- SymBio Seeks EU Clearance to Launch Global PIII Trial of Brincidofovir
July 1, 2025
- Glaucoma Drug Gla-Alpha Approved in Singapore: Kowa
July 1, 2025
- Celltrion’s Stelara Biosimilar to Hit Shelves on July 8
July 1, 2025
- Sanofi Releases Typhim Vi, First Typhoid Vaccine in Japan
July 1, 2025
- Servier Files Tibsovo for Biliary Tract Cancer in Japan
July 1, 2025
- ASKA Rolls Out Contraceptive Pill Slinda in Japan
July 1, 2025
- Average Annual Pay for PMDA Staffers at 7.99 Million Yen in FY2024
July 1, 2025
- 17 of 23 Japan Drug Makers Hike Average Pay in FY2024, 7 Firms Break 10-Million-Yen Mark
July 1, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…